Meet Pharmidex at KTN 2016
June 14, 2016

Collaboration opportunities in regenerative medicine

Pharmdiex will be attending the Innvoate UK KTN 2016 meeting focused on New Collaboration Opportunities in Regenerative Medicine.

The KTN in collaboration with Innovate UK, Cell and Gene Therapy Catapult, Department of Health and Kings College London are holding an event focussing on new unmet clinical needs, latest developments in regulatory environment and clinical adoption. Following recent developments and the UK’s Regenerative Medicine Expert Group report recommendations, this event will bring together the UK regenerative medicine communities involving industrialists, academics and clinicians from a number of clinical specialities.


The UK is leading the field in the development of cell and gene therapies. The regulatory system now has a number of mechanisms to accelerate the progress of promising therapies including EAMS and the proposed new PRIME scheme. However, practical challenges still exist to the clinical adoption of these new therapies and getting them to patients, including generating sufficient clinical data, achieving reimbursement and embedding therapies in existing or new clinical pathways).


Leading clinicians and experts from a number of organisations will be presenting at this event. Directors and managers from major funding organisations, e.g. Innovate UK, Research Councils, relevant charities will also be invited to support this event.


The main aims of this event are as follows;


  • To discuss challenges affecting clinical adoption of cell and gene-based therapies.
  • Facilitate new clinician/industry collaborations in a number of areas of clinical specialities.
  • Identify barriers to innovation and commercialisation.
  • Review current funding opportunities and identify funding gaps.
  • Provide networking opportunities to identify collaborating partners.
  • Review supporting mechanisms available to accelerate innovation and commercialisation through KTN and partners Innovate UK, Cell and Gene Therapy Catapult organisations.
  • Review current pre-clinical and clinical trials and identify best practice to accelerate regulatory approvals


For more information please see the following link: https://www.eventbrite.co.uk/e/new-collaboration-opportunities-in-regenerative-medicine-tickets-24454460951

November 5, 2025
We’re excited to welcome Grace Horne as our new Bioanalytical Scientist! 🎉 Grace brings great enthusiasm and passion for science, and we’re confident she’ll make a fantastic contribution to our team. Welcome aboard, Grace, we’re thrilled to have you with us! 💜
November 4, 2025
We’re pleased to share that Janette Dalay Robertson , Business Development Manager at Pharmidex , will attend the DDW Turning Science into Business Symposium 2025 on Tuesday, 4th November, at the The Francis Crick Institute , London. Janette looks forward to connecting with industry leaders and exploring new collaboration opportunities.
November 3, 2025
We’re delighted to announce that Pharmidex will present our poster "Driving breakthroughs in Parkinson’s & neurodegeneration research” at the upcoming RSC BMCS meeting. With over 23 years of CNS expertise, we support biopharma partners in developing new therapies for Parkinson’s disease and tauopathies, through: 🔹 Parkinson’s & neurodegeneration models 🔹 Transgenic CNS lines (incl. 5xFAD) 🔹 Biomarker & BBB penetration studies Join us in Cambridge to explore how our GLP-accredited CNS platforms accelerate discovery and development.
More Posts